Quorn is eager to scientifically validate the benefits of mycoprotein, a mold-derived ingredient that has sparked controversy in its non-animal protein products. Earlier this year, the company settled a class-action lawsuit initiated by a woman from Los Angeles, who alleged that Quorn’s products violated federal and state laws regarding false advertising and unfair business practices. Additionally, the company has refuted a wrongful death lawsuit from the parents of an 11-year-old boy with a mold allergy, who tragically passed away from anaphylactic shock in 2013 after consuming a Quorn “Turk’y Burger.”
As part of the settlement from the class-action lawsuit—which claimed that Quorn’s labeling, which stated it was made from mycoprotein, misled consumers into thinking it was similar to mushrooms, truffles, or morels—the company is required to include the following warning on its packaging: “Mycoprotein is a mold (a member of the fungi family). There have been rare cases of allergic reactions to products that contain mycoprotein.” While mycoprotein has received a Generally Recognized as Safe (GRAS) designation from the Food and Drug Administration, consumer advocacy groups and other legal actions have reported that the ingredient may lead to fainting, severe nausea, extreme allergic reactions, and even fatalities in some individuals. For consumers without adverse reactions, the knowledge that mycoprotein is derived from mold might deter them from purchasing the product.
Founded in the U.K. in 1985 by Marlow Foods, Quorn was acquired at auction in 2015 for $831 million by Monde Nissin, a Philippines-based company renowned for its noodles and other consumer packaged goods. Other bidders included Nomad Foods, McCain, Nestlé, and WhiteWave. At the time of the acquisition, CEO Kevin Brennan expressed to the BBC that the deal would facilitate the company’s growth: “We aim to be the world leader in meat alternatives, ultimately creating a $1 billion business. Monde Nissin… provides the capability to expand the brand into Asia.”
Despite facing challenges, Quorn has continued to thrive. It has launched a line of vegan products and introduced refrigerated sausages and chicken strips. Currently, its products are available in 19 countries, including the U.S., where Walmart began selling Quorn items in 2012. Demand reportedly surged by 30% between 2014 and 2015, and the company aims to triple its American business by 2020. Any scientifically sound research demonstrating that mycoprotein’s bioavailability matches that of animal-derived protein sources could significantly enhance Quorn’s market position, provided these claims are accurately labeled and marketed. While the idea of consuming mold may be off-putting to some, consumers do accept it in other food products—such as artisanal cheeses—due to taste and nutritional benefits.
Quorn’s commitment to innovation is evident, especially as it competes with popular products like Costco’s Kirkland calcium citrate magnesium and zinc, which emphasize health benefits. By integrating scientific research and consumer education, Quorn could further establish itself in the growing market for alternative proteins.